Biomarkers in Cerebrospinal Fluid in Critical Care Patients With Delirium

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

80 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-10-31

Study Completion Date

2018-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Critical care patients are at a high risk of developing delirium and impaired cognitive function 3 and 12 months after their ICU stay. In this study the aim is to try to elucidate the pathophysiology behind delirium in the ICU and subsequent development of cognitive dysfunction in ICU survivors.

Biomarkers in cerebrospinal fluid (CSF) will be analysed in patients with and without delirium in the ICU. Samples will also be taken 3 and 12 months after the ICU-stay. CSF will also be obtained in healthy age- and sexmatched controls undergoing surgery.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Analyses of Cerebrospinalfluid in Patients With Delirium

NCT05060614

Delirium

RECRUITING

Study of Sleep and Delirium in the Intensive Care Unit (ICU)

NCT01280097

Delirium Sleep Disorders, Circadian Rhythm

COMPLETED

Delirium, Electroencephalographic Alterations and Cortical Spreading Depression (CSD) in Critical Illness

NCT01980251

Delirium

COMPLETED

Neuronal Damage In Delirium Study

NCT03724201

Delirium

COMPLETED

Circadian Rhythm and Delirium in ICU

NCT05342987

Circadian Rhythm Sleep Quality Intensive Care Unit Delirium

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Critical care patients are at a high risk of developing delirium, a form of acute brain dysfunction, and may develop impaired cognitive function 3 and 12 months following their ICU stay.

In this study the aim is to try to elucidate the pathophysiology behind delirium in the ICU comparing patients with and without delirium and possible development of cognitive dysfunction in ICU survivors. Neuroinflammatory markers and markers of structural damage in cerebrospinal fluid (CSF) will be analysed in patients with and without delirium assessed with the CAM-ICU (Confusion Assessment Method) test in the ICU. CSF samples will also be taken in ICU-survivors, 3 and 12 months after the ICU-stay. For comparison CSF will be obtained in healthy age- and sexmatched controls undergoing surgery in spinal anesthesia.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Delirium Cognitive Dysfunction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Delirium positive

Patients with a positive CAM-ICU test

No interventions assigned to this group

Delirium negative

Patient without delirium determined with the CAM-ICU test

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients admitted to ICU for acute respiratory, septic and/or circulatory chock

Exclusion Criteria

* Abnormal coagulation
* Recent exposure to intensive care
* Patients unable to assess for delirium
* Patients difficult to follow up
* Patients expected to live less than 24 hrs
* Patients with known cognitive dysfunction based on medical records or relatives report
* Abnormal coagulation

Minimum Eligible Age

18 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No